Practical implication
Clinical safety and pharmacovigilance teams must update their study protocols and adverse event reporting procedures to align with the revised guidance by October 2, 2026.
The FDA has released a revised draft guidance for industry detailing study designs to assess the irritation and sensitization potential of transdermal and topical delivery systems (TDS) for abbreviated new drug applications (ANDAs). This updated guidance includes new parameters for study design, clinical endpoints, and reporting expectations, particularly focusing on localized adverse reactions. The guidance is intended to align generic product safety reporting with current FDA expectations.
What changed: The guidance now specifies updated methodologies for assessing skin irritation and sensitization in clinical studies associated with ANDAs, including new clinical endpoint parameters and reporting obligations related to localized adverse reactions.
Why it matters: Compliance with these revised expectations is critical for ensuring the safety and efficacy of generic topical products and maintaining consistency in safety reporting protocols.
Practical implication: Clinical safety and pharmacovigilance teams must update their study protocols and adverse event reporting procedures to align with the revised guidance by October 2, 2026.
View original source
Published from the Firecrawl policy change extraction pipeline.
